New Wave of Securities Investigations Launched
Investor rights law firms are launching a new round of securities investigations. Rosen Law Firm is now probing potential claims against Nidec Corporation, while Faruqi & Faruqi is investigating Aquestive Therapeutics and Hub Group for potential violations.
The probe into Nidec Corporation follows the company's announcement of an internal investigation into alleged improper accounting at one of its units in China. This disclosure resulted in Nidec's American Depositary Receipts (ADRs) plummeting by 22.7% on September 4, 2025, marking the largest single-day drop in the company's history. Further details emerged revealing that the internal probe found documents suggesting management's involvement in or knowledge of the improper accounting. Subsequently, Nidec's auditor issued a disclaimer of opinion, and the company withdrew its year-end forecast. Aquestive Therapeutics is under scrutiny after the U.S. Food and Drug Administration (FDA) identified deficiencies in the company's New Drug Application for Anaphylm, a sublingual film for treating severe allergic reactions. The FDA's notification, which did not specify the deficiencies, precludes discussions on labeling and post-marketing commitments at this time. Following the news on January 9, 2026, shares of Aquestive Therapeutics plunged by approximately 40%. The investigation focuses on whether the company made false or misleading statements to investors regarding the drug's approval prospects. The investigation into Hub Group, a major freight transportation provider, was triggered after the company announced it would need to restate its financial statements for the first three quarters of 2025. The restatement is necessary due to an error that understated purchased transportation costs and accounts payable. On February 6, 2026, following the disclosure of the accounting error, Hub Group's shares fell by as much as 25% during intraday trading. The investigations by firms like Faruqi & Faruqi are examining whether the logistics company violated federal securities laws by making false and misleading statements to investors. These securities law firms often work on a contingency basis, meaning investors are not responsible for out-of-pocket fees or court costs. If the investigations lead to successful class-action lawsuits, the firms seek to recover financial losses on behalf of the affected shareholders.
